Epizyme, Inc.
EPZM
|
$1.47
-1.34%
0.0%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-1.7% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar: 2022-08-08
Market Cap: $ 247,496,185
http://www.epizyme.com
Sec Filling | Patents | 203 employees
(US) Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.
cancer ovarian cancer t-cell lungs genetic leukemia ceiling
Drugs
TAZVERIK (tazemetostat)add to watch list Paper trade email alert is off
Biocept, Inc.
BIOC
|
$0.4349
-10.32%
750K
|
Health Services
(0.0% 1d) (0.0% 1m) (58.3% 1y) (0.0% 2d) (0.0% 3d) (-13.1% 7d) (-9.6% volume)
Earnings Calendar: 2023-04-17
Market Cap: $ 1,142,059
http://www.biocept.com
Sec Filling | Patents | 88 employees
(US) Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support and specific oncogenic alterations. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.
tumor cells t-cell clinical trials ceiling
add to watch list Paper trade email alert is off
Brickell Biotech, Inc.
BBI
|
$2.12
16.04%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-74.2% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 6,092,806
http://www.brickellbio.com
Sec Filling | Patents | 15 employees
(US) Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.
dermatitis skin t-cell treatment ceiling
add to watch list Paper trade email alert is off
Aravive, Inc.
ARAV
|
$0.0401
4.74%
4M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-97.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-85.6% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 2,949,862
http://www.aravive.com
Sec Filling | Patents | 17 employees
(US) Aravive, Inc. is a clinical-stage biotechnology company, which engages in developing new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments, and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.
cancer t-cell ovarian cancer treatment ceiling
add to watch list Paper trade email alert is off
Celyad SA
CYAD
|
$0.47
-12.49%
49K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-34.7% 1y) (0.0% 2d) (-11.1% 3d) (0.0% 7d) (421.67% volume)
Earnings Calendar:
Market Cap: $ 10,619,159
http://www.celyad.com
Sec Filling | Patents | 107 employees
(BE) Celyad Oncology SA engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
cancer cardiology car-t t-cell treatment ceiling
add to watch list Paper trade email alert is off
Athersys, Inc.
ATHX
|
$0.1018
-40.86%
95M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-87.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (46.93% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 2,290,644
http://www.athersys.com
Sec Filling | Patents | 83 employees
(US) Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.
cardiovascular stem cell urea t-cell neurological ceiling
add to watch list Paper trade email alert is off
Avalon GloboCare Corp.
AVCO
|
$0.45
-16.15%
31.11%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-14.4% 3d) (0.0% 7d) (32.38% volume)
Earnings Calendar:
Market Cap:
http://www.avalon-globocare.com
Sec Filling | Patents | 8 employees
Avalon GloboCare Corp. is a holding company, which engages in the development of biotechnology and provision of healthcare services. It operates through the following segments: Real Property Operating; Medical Related Consulting Services; and Development Services and Sales of Developed Products. It offers regenerative medicine, cell-based immunotherapy, exosome technology, and rehabilitation medicine through Avalon Cell and Avalon Rehab platforms. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.
immunotherapy t-cell ceiling
add to watch list Paper trade email alert is off
Akouos, Inc.
AKUS
|
$13.29
1.07%
3.46%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2022-11-11
Market Cap:
http://www.akouos.com
Sec Filling | Patents | 54 employees
Akouos, Inc. engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA.
gene therapies t-cell genetic hearing loss ceiling
add to watch list Paper trade email alert is off
Forma Therapeutics Holdings, Inc.
FMTX
|
$20.01
-0.15%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 957,529,666
https://formatherapeutics.com
Sec Filling | Patents | 105 employees
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA.
cancer prostate cancer t-cell treatment ceiling
add to watch list Paper trade email alert is off
Genocea Biosciences, Inc.
GNCA
|
$0.051
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-15.0% 3d) (0.0% 7d) (-35.74% volume)
Earnings Calendar: 2022-08-04
Market Cap:
http://www.genocea.com
Sec Filling | Patents | 59 employees
(US) Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
vaccine cancer immunotherapy t-cell genetic treatment ceiling
add to watch list Paper trade email alert is off
Global Blood Therapeutics, Inc.
GBT
|
$68.49
0.02%
-0.02%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (73.96% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 4,621,443,500
http://www.gbt.com
Sec Filling | Patents | 352 employees
(US) Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.
t-cell ceiling
Drugs
OXBRYTA (Voxelotor)add to watch list Paper trade email alert is off
Harpoon Therapeutics, Inc.
HARP
|
$23.01
0.07%
6.6M
|
Health Technology
(0.0% 1d) (0.0% 1m) (3909.4% 1y) (0.0% 2d) (0.1% 3d) (0.0% 7d) (122.25% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 389,611,579
http://www.harpoontx.com
Sec Filling | Patents | 61 employees
(US) Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTACs) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.
cancer immunotherapy glass t-cell treatment ceiling construction
add to watch list Paper trade email alert is off
Meridian Bioscience Inc.
VIVO
|
$33.97
0.0%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.7% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar: 2023-02-03
Market Cap: $ 1,488,831,011
http://www.meridianbioscience.com
Sec Filling | Patents | 750 employees
(US) Meridian Bioscience, Inc. engages in the development, manufacture, sale, and distribution of diagnostic test kits, antigens, reagents, and related products. It operates through the following segments: Diagnostics and Life Science. The Diagnostics segment consists testing platforms and technologies such as Isothermal DNA Amplification, Rapid Immunoassay, Enzyme-linked Immunoassay, and Anodic Stripping Voltammetry. The Life Science segment distributes bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.
antibody t-cell diagnostics ceiling
add to watch list Paper trade email alert is off
Midatech Pharma PLC
MTP
|
$0.4703
-70.79%
-73.69%
0
|
Health Technology
(0.0% 1d) (-11.4% 1m) (0.0% 1y) (-11.4% 2d) (-11.4% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 3,260,999
http://midatechpharma.com/
Sec Filling | Patents | n/a employees
Midatech Pharma Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in house programmes as well as partnered programmes. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is a innovative nanosaccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is a edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale ie i. chemotherapy - improved and targeted delivery of existing chemotherapeutic agents to tumor sites, as well as ii. immunotherapy - enhanced uptake of new immuno-moieties by immune cells that can then mount an immune attack against cancer cells. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
cancer immunotherapy t-cell drug delivery housing ceiling
add to watch list Paper trade email alert is off
Otonomy, Inc.
OTIC
|
$0.077
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-11.6% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2023-02-28
Market Cap: $ 4,400,819
http://www.otonomy.com
Sec Filling | Patents | 49 employees
Otonomy, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Ménière's disease; OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT); OTO-313 (gacyclidine) tinnitus; OTO-413 (BDNF) hidden hearing Loss; OTO-510 (otoprotectant) prevent CIHL; OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan in April 2008 and is headquartered in San Diego, CA.
t-cell brands hearing loss ceiling
Drugs
Otiprio (ciprofloxacin)add to watch list Paper trade email alert is off
Pluristem Therapeutics, Inc.
PSTI
|
$1.0
-2.91%
8.0%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (192.0% volume)
Earnings Calendar: 2022-09-12
Market Cap: $ 32,347,584
http://www.pluristem.com
Sec Filling | Patents | 146 employees
(IL) Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
israel t-cell clinical trials treatment ceiling
add to watch list Paper trade email alert is off
Jounce Therapeutics, Inc.
JNCE
|
$1.88
-2.59%
-1.85%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (-1.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2023-05-04
Market Cap: $ 98,954,680
http://www.jouncetx.com
Sec Filling | Patents | 130 employees
(US) Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.
cancer immunotherapy t-cell ceiling
add to watch list Paper trade email alert is off
Humanigen, Inc.
HGEN
|
$0.0361
-61.5%
120M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-77.2% 1y) (0.0% 2d) (0.0% 3d) (-81.1% 7d) (23283.32% volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 4,298,793
http://www.humanigen.com
Sec Filling | Patents | 2 employees
(US) Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA.
cancer gene therapies t-cell treatment ceiling
add to watch list Paper trade email alert is off
IMV Inc.
IMV
|
$0.8225
-2.74%
45K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-2.5% 1y) (-2.5% 2d) (-2.5% 3d) (0.0% 7d) (-76.64% volume)
Earnings Calendar: 2023-05-12
Market Cap: $ 9,632,821
http://www.imv-inc.com
Sec Filling | Patents | n/a employees
IMV, Inc. is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company leverages its delivery platform (DPX) that programs immune cells directly within the human body to produce robust and sustained target killing capabilities. Its drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple phases 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma) where it has identified a predictive biomarker. The company was founded by Warwick Kimmins and Brian E. Lowe on May 18, 2007 and is headquartered in Dartmouth, Canada.
vaccine covid cancer ovarian cancer immunotherapy infectious disease glass t-cell ceiling
add to watch list Paper trade email alert is off
ANGLE plc
ANPCF
|
News
|
$0.148
641.22%
5K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-11.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1011.11% volume)
Earnings Calendar:
Market Cap: $ 38,565,921
https://angleplc.com
Sec Filling | Patents | n/a employees
(GB) ANGLE Plc operates as a holding company, through its subsidiaries engages in providing products in cancer diagnostics and foetal health. Its main product is the Parsortix cell separation system, which can capture very rare cells from blood. The company was founded by Andrew D. W. Newland in April 1994 and is headquartered in Guildford, the United Kingdom.
msa ceiling diagnostics cancer t-cell
add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10